Monitor for any upcoming regulatory or clinical catalysts for EB613 (oral PTH(1-34) for osteoporosis), as the board refresh signals preparation for late-stage commercialization. No immediate financial impact from this routine board change.
Price Chart
Executive Summary
Entera Bio appointed former Gilead and Amgen executive Laura Hamill to its Board of Directors, effective December 1, 2026, while director Yonatan Malca steps down on the same date. The appointment adds deep commercial expertise as the company prepares for late-stage clinical execution and potential commercialization of its lead candidate EB613.
Key Facts
- Laura Hamill appointed as Class I director, effective December 1, 2026
- Hamill will serve on audit committee and corporate governance and nomination committee
- Yonatan Malca stepping down as director effective December 1, 2026, with no disagreement cited
- Hamill is a former EVP Worldwide Commercial Operations at Gilead and spent nearly two decades at Amgen
- Hamill currently serves on boards of Jazz Pharmaceuticals (JAZZ), BB Biotech AG, and Fate Therapeutics (FATE)
Financial Impact
No financial figures disclosed; standard non-employee director compensation applies
Risk Factors
- Clinical-stage company with no approved products; reliance on pipeline advancement
- Forward-looking statements regarding EB613 and platform are aspirational with no guarantee of regulatory success
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-004720 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-004720 |
| Document: 0001178913-26-004720-index-headers.html | 0001178913-26-004720 |
| Document: 0001178913-26-004720-index.html | 0001178913-26-004720 |
| Document: 0001178913-26-004720.txt | 0001178913-26-004720 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.86 (+3.25%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.86 (+13.04%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.86 (−7.14%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.86 (−1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.86 (−5.92%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.86 (−4.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.86 (+142.37%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.86 (+134.43%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.86 (+132.52%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.86 (+144.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers